One of the most challenging situations in recent years that protein engineers faced was producing and developing biopharmaceuticals. Furthermore, it should withstand the conditions of gastrointestinal serums and tracts. This is one of the challenges conveyed at the PEGS Summit conducted by Cambridge Healthtech. In order to meet the requirements, Manuel Vega demonstrated a 2D scanning way to identify the single residue alteration.
Such an approach comprises some experimental scans of sites. This takes place across the sequence of linear peptides. Vega says that all the proteolysis sites that matter have been identified. Some of these sites play a significant role in impacting the Vivo half-life. Another notable aspect is that the proteins that are proteolysis-resistant tend to show longer half-lives amid gastrointestinal tracts. This allows the absorption to take place via a barrier. Following such a process will open the window for the therapeutic proteins’ oral administration.
Therapeutic Protease Engineering
Protease activities are not the problems you can always avoid. You can, however, exploit the human protease as biologics. There are some significant problems with the applications of therapeutic proteases. Some of these problems include inactivity, no specification, and rapid inactivation. This takes place by the active protease inhibitor, which is naturally occurring in the human serum. Another notable factor is the protein production that you will get familiar with the article.
The vice-president of the protein engineering department, Direvo Biotech, presented one of the strategies. It uses confocal fluorimetry screening and combinatorial libraries to develop a not so specific human protease and trypsin. The scientists managed to accomplish the objective while forming the trypsin variant with the 80-fold increase amid certain activities. Furthermore, with many thousand-fold fewer inhibitions amidst the IC50 (100 percent human serum). The department said that their distinctive strategies in 100 percent serum (human) represent a platform for the process of therapeutic proteases’ optimization.
Lysosomal Storage Diseases
It is essential to know that therapeutic advancements are a crucial driving force that pushes protein engineering in the right direction. But, it is necessary to understand the biology behind such a process as well. The Vice President of Genzyme’s protein research department, Tim Edmunds, focusses on protein targeting. In this, the replacement therapy of an enzyme is readily available for many lysosomal diseases like the Gaucher one.
In particular, this disease is one of the inherited diseases that allow people to absorb fatty glucocerebroside. This specific cycle prevents organs and cells from functioning in the right manner. The blood transfusions can send back many disease phenotypes like an abnormal blood count and extended liver size. Unlike the cell-surface proteins, cells should interact with the lysosomal storage protein. Another set of challenges that breakthrough are in the shape of immunogenicity. This takes place in patients who lack genetically. Furthermore, such patients detect transfused enzymes as a foreign body.
The department explained that they utilized several types of techniques to observe storage disease proteins modifying. Carbohydrates need to go through the process of remodeling to deliver efficiently to macrophages. Genzyme later reported that its department accomplished such a result with the help of Cerezyme. Cerezyme is the recombinant production of the company. In this, the protein’s sugar moieties cut back themselves to expose the residues of terminal mannose. Such a process later increases the uptake twofold of macrophage.
The department’s researchers followed the recombinant glucocerebrosidase amid the cell lines of baculovirus to increase the mannose-binding sites. The result of this entire process was mannose chain lengths that run from three to nine. However, this has little impact on the protein’s distribution. They also studied the potential changes in amino acids. It took place to cut the dosage requirement. Moreover, they have PEGylated the variants of a protein that are under animal system observation. The department thus concluded that they are trying to decipher the mechanism and biology as it is not an imminent product.
Tyrosine Kinase Receptors
High throughput is essential when it comes to target identification. MedImmune states that their all-new filter approach tends to improve the performance since every 10 centimeters filter comprises nearly 30 million antibody clones of the phage-expression library. As the density of the clone increases, the chances of a confluence leap too. This makes the process of distinguishing individual clones a bit challenging.
These receptors can be referred to as cell surface high-affinity receptors for several cytokines, polypeptide growth factors, and hormones. Out of 90 distinctive genes of tyrosine kinase observed amid a human genome, nearly 58 tend to encode the tyrosine kinase proteins’ receptor.
With the help of tagged (high-affinity) antibody fusion proteins, the researchers overcame such a hurdle. Moreover, they could increase the sensitivity of the screen as well. Also, MedImmune focuses on the receptor – A4 tyrosine kinase receptor that further implicates amid cancer cells. Such a process takes place as a model system and manages to locate the target under one week. In normal circumstances, the process usually takes around thirty days from a substrate to a particular goal.